BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
Chandra J Cohen-StaviOri MagenNoam BardaShlomit YaronAlon PeretzDoron NetzerCarlo GiaquintoAli JuddLeonard LeiboviciMiguel A HernánMarc LipsitchBen Y ReisRan D BalicerNoa DaganPublished in: The New England journal of medicine (2022)
Our findings suggest that as omicron was becoming the dominant variant, two doses of the BNT162b2 messenger RNA vaccine provided moderate protection against documented SARS-CoV-2 infection and symptomatic Covid-19 in children 5 to 11 years of age. (Funded by the European Union through the VERDI project and others.).